OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
Globenewswire·2025-09-04 16:00
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation NANTES, France – September 4, 2025, 6 p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reaffirms its strategic commitment to value creation ahead of the September 30 Annual General Meeting. The Company is focused on developing innovative therapies in immuno-oncology and immuno-inflammation, supported by a robust and differentiated portfolio, a cutting-edge research platform, and stable ...